Health Intervention and Technology Assessment Program (HITAP), Nonthaburi, Nonthaburi, Thailand OBJECTIVES: In Thailand two approaches for cervical cancer screening, namely Pap smear and visual inspection with acetic acid (VIA), are introduced in the public sector. This study aims to assess the service coverage and the factors associating with screening test seeking behavior in two provinces, namely Chiangmai and Nakon Si Thammarat. METHODS: A cross-sectional household survey was conducted in 2009 in the two study provinces, among women aged 30-60 years old. A total of 1600 women were randomly selected by stratifi ed four-stage sampling. Of these, 1577 were interviewed (98% respondent rate). Descriptive statistics and logistic regression were used in the data analysis. RESULTS: This study suggests that the coverage rates of cervical screening tests in the past 5 years were relatively high; 76% in Chiangmai and 70% in Nakon Si Thammarat. In both provinces, Pap smear was more commonly introduced than the VIA around two to three times. The most common reasons for not seeking screening tests was "the absence of symptoms," followed by "the lack of time" and "feeling shy toward health workers." A multivariate logistic regression analysis indicates that supporting and impeding factors of the screening service seeking behavior were signifi cantly associated with screening test. Women with the following characteristics were more likely to seek the tests than others: age 40-50 years, agriculture occupation, child-bearing experience, cervical cancer history in family member, and ever exposing to the information regarding cervical cancer and screening tests. Meanwhile, respondents who were less likely than others to seek the screening services included cigarette smokers. CONCLUSIONS: There were several factors associating with the service seeking practices among women in these settings. In order to increase the service uptake, it is suggested that extensive education program concerning cervical cancer and screenings should be provided with the aim to abolish the misunderstandings and increase awareness among target population. , and meta-analysis of RCT of adjuvant chemotherapy for patients with stage III colon cancer were included by searching through the Medline and Cochrane databases. The clinical effi cacy studies of three adjuvant chemotherapy regimens on improving survival outcomes of patients with stage III colon cancer were included. Indirect or mixed-treatment comparison meta-analysis with fi x effect model was applied to combine results of several studies. The meta-analysis was carried out using Bayesian approach and WinBUGS14 software program. The summary effi cacy of adjuvant chemotherapy were presented as odds ratio (OR) and its 95% confi dence interval (CI). To test the variation of study outcomes between studies, heterogeneity test was also applied. RESULTS: Total of 714 abstracts were reviewed and four eligible studies related to adjuvant chemotherapy for patients with stage III colon cancer were included in the meta-analysis. Two studies compared oral capectitabine with 5-FU/LV, while one study compared FOLFOX4 with 5-FU/LV. Indirect comparison was used to compare FOLFOX 4 and oral capecitabine. When compared to 5-FU/LV, FOLFOX4 and oral capecitabine could signifi cantly reduce the risk of death by 23% (OR = 0.77, 95% CI = 0.68-0.86) and 16% (OR = 0.84, 95% CI = 0.72-0.98), respectively. Moreover, the OR of mortality among patients treated by oxaliplatin plus 5-FU/LV was 0.92 (95% CI = 0.76-1.11) compared to capecitabine. CONCLUSIONS: Of three regimens for patients with adjuvant chemotherapy stage III colon cancer, FOLFOX4 could signifi cantly yield the longest patient survival, followed by capecitabine and 5-FU/LV. However, FOLFOX4 did not signifi cantly reduce mortality events compared with capecitabine.
very few studies have analyzed the agreement between patients and proxy ratings on patients' QOL. The objective of this study was to compare PRO of quality of life and proxy assessment using EORTC QLQ PAL-15. METHODS: We administered the EORTC QLQ PAL-15 to 32 patients and their own family, nurse and doctor, respectively as proxies of patient. The QLQ PAL-15 is a 15-item shortened version of the EORTC QLQ-C30 cancer-specifi c health-related quality of life measure consisting of two functional scale (physical and emotional), seven symptom scale (fatigue, pain, nausea and vomiting, dyspnea, appetite loss, insomnia, constipation), and single-item scale to assess quality of life. The analyses focused on intraclass correlation coeffi cients (ICCs) to comparing the ICC 95% lower confi dence interval with critical value 0.70 and Pearson's correlation coeffi cients. RESULTS: Agreement between patients and proxies on the scales was excellent for physical function (ICC = 0.889) and fatigue (ICC = 0.739). Emotional function, emesis, pain, appetite loss, constipation, constipation and quality of life scale was fair agreement (ICC range from 0.471 to 0.739). Dyspnea (ICC = 0.301) and insomnia (ICC = 0.097) was poor agreement between PRO and proxies assessment. There were higher correlation with family than other proxies with patient in emotional function (r = 0.791, P < 0.001), insomnia (r = 0.774, P < 0.001), nausea and vomiting (r = 0.646, P < 0.001), appetite loss (r = 0.638, P < 0.001), dyspnonea (r = 0.402, P < 0.005). There were higher correlation with nurse than other proxies with patient in physical function (r = 0.791, P < 0.001) and constipation (r = 0.540, P < 0.001). There were higher correlation with doctor than other proxies in pain(r = 0.494, P < 0.001), and fatigue (r = 0.406, P < 0.005). CONCLU-SIONS: The agreement between PROs and proxies assessment in QOL assessment is different by symptom and function. Family caregiver were more agreement than nurse and doctor. We need to paid attention to proxy assessment more carefully.
